Official Positions for FRAX® Clinical Regarding Glucocorticoids: The impact of the Use of Glucocorticoids on the Estimate by FRAX® of the 10 Year Risk of Fracture. From Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®M

Journal of Clinical Densitometry

Volumn 14, Issue 3, 2011, Pages 212-219

  Leib, Edward S ^a   Saag, Kenneth G ^b   Adachi, Jonathan D ^c   Geusens, Piet P ^d   Binkley, Neil ^e   McCloskey, Eugene V ^f   Hans, Didier B ^g  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c MCMASTER UNIVERSITY   (Canada)

^d MAASTRICHT UNIVERSITY   (Netherlands)

^e UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^f UNIVERSITY OF SHEFFIELD   (United Kingdom)

^g LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Drug induced osteoporosis; Fracture risk; FRAX; Glucocorticoids

Indexed keywords

BECLOMETASONE; BECLOMETASONE DIPROPIONATE; GLUCOCORTICOID; PLACEBO; PREDNISOLONE; PREDNISONE; RISEDRONIC ACID;

ADRENAL INSUFFICIENCY; ARTICLE; ASTHMA; BONE DENSITY; BONE REMODELING; CALCULATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE DURATION; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG MEGADOSE; FOREARM FRACTURE; FRACTURE; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; LUMBAR SPINE; MEDICAL LITERATURE; MEDICAL SOCIETY; META ANALYSIS; OSSIFICATION; OSTEOLYSIS; PHYSICIAN; POSTMENOPAUSE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROBABILITY; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SPINE FRACTURE; SYSTEMATIC REVIEW; TRABECULAR BONE; TREATMENT DURATION; VERTEBRA FRACTURE;

ADMINISTRATION, ORAL; ALGORITHMS; DIAGNOSIS, COMPUTER-ASSISTED; FRACTURES, BONE; GLUCOCORTICOIDS; HUMANS; MODELS, STATISTICAL; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; PREDNISOLONE; RISK ASSESSMENT; RISK FACTORS;

EID: 79960919567     PISSN: 10946950     EISSN: 15590747     Source Type: Journal    
DOI: 10.1016/j.jocd.2011.05.014     Document Type: Article

References (49)

1. Cushing H. The basophilic adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Bull John Hopkins Hosp 1932, 1:137-142.
2. van Staa T.P., Leufkens H.G., Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002, 13(10):777-787.
3. Van Staa T.P., et al. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 2003, 48(11):3224-3229.
4. Saag K.G. Prevention of glucocorticoid-induced osteoporosis. South Med J 2004, 97(6):555-558.
5. Saag K.G., et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 2009, 60(11):3346-3355.
6. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum 2001, 44(7):1496-1503.
7. Eastell R., et al. A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med 1998, 244(4):271-292.
8. Grossman J.M., et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 2010, 62(11):1515-1526.
9. Kanis JA JH, Oden A, McCloskey EV. 2010 Guidance for the adjustment of FRAX® according to the dose of glucocorticoids. WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield.
10. Van Staa T.P., et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000, 15(6):993-1000.
11. van Staa T.P., et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 2000, 39(12):1383-1389.
12. Kanis J.A., et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004, 19(6):893-899.
13. Marshall D., Johnell O., Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996, 312(7041):1254-1259.
14. van Staa T.P., et al. A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids. QJM 2005, 98(3):191-198.
15. Laan R.F., et al. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study. Ann Intern Med 1993, 119(10):963-968.
16. Ton F.N., et al. Effects of low-dose prednisone on bone metabolism. J Bone Miner Res 2005, 20(3):464-470.
17. De Vries F., et al. Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum 2007, 56(1):208-214.
18. van Staa T.P., et al. Are inhaled corticosteroids associated with an increased risk of fracture in children?. Osteoporos Int 2004, 15(10):785-791.
19. Barnes N.C. The properties of inhaled corticosteroids: similarities and differences. Prim Care Respir J 2007, 16(3):149-154.
20. Johnell O., et al. Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler. Eur Respir J 2002, 19(6):1058-1063.
21. Weatherall M., et al. Dose-response relationship for risk of non-vertebral fracture with inhaled corticosteroids. Clin Exp Allergy 2008, 38(9):1451-1458.
22. Etminan M., et al. Inhaled corticosteroids and the risk of fractures in older adults: a systematic review and meta-analysis. Drug Saf 2008, 31(5):409-414.
23. Richy F., et al. Inhaled corticosteroids effects on bone in asthmatic and COPD patients: a quantitative systematic review. Osteoporos Int 2003, 14(3):179-190.
24. Drummond M.B., et al. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008, 300(20):2407-2416.
25. de Vries F., et al. Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population-based case-control study. J Intern Med 2007, 261(2):170-177.
26. van Staa T.P., Leufkens H.G., Cooper C. Use of inhaled corticosteroids and risk of fractures. J Bone Miner Res 2001, 16(3):581-588.
27. Hubbard R.B., et al. Inhaled corticosteroids and hip fracture: a population-based case-control study. Am J Respir Crit Care Med 2002, 166(12 Pt 1):1563-1566.
28. Nuti R., et al. Vertebral fractures in patients with chronic obstructive pulmonary disease: the EOLO Study. Osteoporos Int 2009, 20(6):989-998.
29. Gonnelli S., et al. Effect of inhaled glucocorticoids and beta(2) agonists on vertebral fracture risk in COPD patients: the EOLO study. Calcif Tissue Int 2010, 87(2):137-143.
30. Vestergaard P., Rejnmark L., Mosekilde L. Fracture risk associated with systemic and topical corticosteroids. J Intern Med 2005, 257(4):374-384.
31. Suissa S., et al. Inhaled and nasal corticosteroid use and the risk of fracture. Am J Respir Crit Care Med 2004, 169(1):83-88.
32. Schoon E.J., et al. Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease. Clin Gastroenterol Hepatol 2005, 3(2):113-121.
33. Cino M., Greenberg G.R. Bone mineral density in Crohn's disease: a longitudinal study of budesonide, prednisone, and nonsteroid therapy. Am J Gastroenterol 2002, 97(4):915-921.
34. Zorzon M., et al. Long-term effects of intravenous high dose methylprednisolone pulses on bone mineral density in patients with multiple sclerosis. Eur J Neurol 2005, 12(7):550-556.
35. Ahmadpoor P., et al. Osteoporosis and related risk factors in renal transplant recipients. Transplant Proc 2009, 41(7):2820-2822.
36. Haugeberg G., et al. Bone loss in patients treated with pulses of methylprednisolone is not negligible: a short term prospective observational study. Ann Rheum Dis 2004, 63(8):940-944.
37. Lems W.F., et al. Changes in (markers of) bone metabolism during high dose corticosteroid pulse treatment in patients with rheumatoid arthritis. Ann Rheum Dis 1996, 55(5):288-293.
38. Peacey S.R., et al. Glucocorticoid replacement therapy: are patients over treated and does it matter?. Clin Endocrinol (Oxf) 1997, 46(3):255-261.
39. Lovas K., et al. Glucocorticoid replacement therapy and pharmacogenetics in Addison's disease: effects on bone. Eur J Endocrinol 2009, 160(6):993-1002.
40. Heureux F., et al. [Evaluation of corticosteroid replacement therapy and its effect on bones in Addison's disease]. Ann Endocrinol (Paris) 2000, 61(3):179-183.
41. Florkowski C.M., et al. Bone mineral density is reduced in female but not male subjects with Addison's disease. N Z Med J 1994, 107(972):52-53.
42. Zimmermann A., et al. Bone mineral density and bone turnover in Romanian children and young adults with classical 21-hydroxylase deficiency are influenced by glucocorticoid replacement therapy. Clin Endocrinol (Oxf) 2009, 71(4):477-484.
43. Sciannamblo M., et al. Reduced bone mineral density and increased bone metabolism rate in young adult patients with 21-hydroxylase deficiency. J Clin Endocrinol Metab 2006, 91(11):4453-4458.
44. Falhammar H., et al. Fractures and bone mineral density in adult women with 21-hydroxylase deficiency. J Clin Endocrinol Metab 2007, 92(12):4643-4649.
45. Jaaskelainen J., Voutilainen R. Bone mineral density in relation to glucocorticoid substitution therapy in adult patients with 21-hydroxylase deficiency. Clin Endocrinol (Oxf) 1996, 45(6):707-713.
46. Valero M.A., et al. Bone density and turnover in Addison's disease: effect of glucocorticoid treatment. Bone Miner 1994, 26(1):9-17.
47. Jodar E., et al. Long-term follow-up of bone mineral density in Addison's disease. Clin Endocrinol (Oxf) 2003, 58(5):617-620.
48. Braatvedt G.D., et al. Bone mineral density in patients with treated Addison's disease. Osteoporos Int 1999, 10(6):435-440.
49. Zelissen P.M., et al. Effect of glucocorticoid replacement therapy on bone mineral density in patients with Addison disease. Ann Intern Med 1994, 120(3):207-210.